AkriVita
Private Company
Funding information not available
Overview
AkriVita is a private, pre-revenue medical device company founded in 2019 and headquartered in San Diego, California. It has developed a proprietary platform for 3D-printing silica-based microcapillary needles with innovative features like a MultiPort design and sealed fine-point tips to address common industry pain points such as needle clogging, inconsistent delivery, and poor visibility. Targeting the dermatology and broader life sciences sectors, AkriVita's value proposition centers on accelerating biomedical research and improving clinical outcomes through superior precision and customization in microinjection tools.
Technology Platform
Proprietary 3D-printing platform using a silica-based resin to manufacture microcapillary needles with innovative features like a MultiPort design (multiple side ports to reduce clogging), sealed fine-point tips for precision, and high-contrast materials for visibility. Enables customizable needle geometries with pre-calibrated consistency.
Opportunities
Risk Factors
Competitive Landscape
AkriVita competes against traditional glass microcapillary needles, which are inexpensive but inconsistent, and potentially against other emerging advanced manufacturing approaches. Established players like Eppendorf and The Drummond Scientific Company dominate the current market but have not yet commercialized a comparable 3D-printed, multi-port needle system.